Dr Mohsen Ali Asgari obtained his MSc in Analytical Chemistry and graduated in 2011. During his postgraduate time, he worked on a project in selective sorption and determination of Atenolol in pharmaceutical and biological samples by molecular imprinting using new copolymer beads as a functional matrix. In 2020, He obtained his Ph.D. in Pharmaceutical Nano Chemistry at the Institute of Medical Science and Technology (IMSaT) at Keele University. His thesis title was in use of hybrid iron oxide-silver nanoparticles for thermo-responsive drug delivery in pancreatic cancer, under the supervision of Dr Clare Hoskins and Dr Anthony Curtis. He worked on a project to test novel nano HNPs characterization, cytotoxic effect, and cellular interaction of the nanoparticles. He carried out extensive cell culture experiments on a broad range of assays to produce a full cytotoxic profile of the particles and allowed for a greater understanding of the interaction with cells.
In 2021, Dr Ali Asgari, expanded his skills as a Post-Doctoral Researcher, under the supervision of Prof William Griffiths and Prof Yuqin Wang, progressing into developing and applying novel mass spectrometric techniques and instrumentation on neurobiology, looking at lipidomics, especially cholesterol metabolism (sterol and oxysterol markers), and its relation to human health and disease, in particular neurodegenerative diseases. Current project, funded by CHDI, is Sterols as Lipid Biomarkers for Huntington’s disease. He works on a large cohort of human Plasma and CSF samples to find the biomarkers.
Dr Ali Asgari’s research interests are in lipidomics, bile acid biosynthesis and lipid biochemistry, particularly in relation to neurodegenerative disease and the immune system. Dr Ali Asgari is a member of the British Mass Spectrometry Society and the Royal Society of Chemistry.